The human gut may reveal Parkinson’s disease years before tremors or stiffness appear, according to a new British study linking specific bacterial patterns to both patients and genetically at-risk individuals.
Researchers at University College London analyzed stool samples from 271 people with Parkinson’s, 43 asymptomatic carriers of the high-risk GBA1 gene variant, and 150 healthy controls from the UK and Italy. They found that 176 bacterial species differed in abundance between Parkinson’s patients and healthy individuals. Of those, 142 similarly showed abnormal levels in the symptom-free GBA1 carriers, placing their gut flora somewhere between that of healthy people and those already diagnosed.
Study lead Anthony Schapira said the findings strengthen growing evidence of a gut-brain connection in Parkinson’s, suggesting intestinal microbes could serve as an early warning signal for increased risk — potentially years before symptoms emerge. He noted that even a little subset of the healthy control group displayed microbiomes resembling those of at-risk individuals, though it remains unclear whether these people will head on to develop the disease.
The research does not yet offer a ready-to-use diagnostic test but presents a possible pathway toward earlier detection. In Austria alone, around 25,000 people live with Parkinson’s, a condition marked by the progressive loss of dopamine-producing neurons in the midbrain, leading to movement difficulties, rigidity, and resting tremor. Although not curable, symptoms are often manageable with treatment, making early identification increasingly valuable.
This operate aligns with broader efforts to detect neurodegenerative diseases through biological markers before clinical signs appear. Similar advances have emerged in Alzheimer’s research, where blood-based tau protein levels now aid predict symptom onset years in advance. Scientists at the University of East Anglia recently proposed another blood test targeting metabolic byproducts of gut bacteria to identify early cognitive decline, reinforcing the idea that the gut-brain axis may hold clues to multiple forms of dementia.
Historically, efforts to predict Parkinson’s have relied on imaging or genetic screening, neither of which captures the dynamic interplay between microbiome shifts and disease progression. The current approach mirrors past shifts in cancer screening, where liquid biopsies transformed early detection by identifying molecular traces long before tumors became visible.
Can a stool sample really predict Parkinson’s before symptoms start?
The study found that people with the high-risk GBA1 gene variant but no symptoms already showed gut bacteria patterns similar to those of Parkinson’s patients, suggesting the microbiome may shift years before clinical signs appear. However, researchers caution this is not yet a diagnostic tool and requires further validation.
Why focus on the gut when Parkinson’s is a brain disease?
Growing evidence shows the gut and brain communicate via the vagus nerve, immune pathways, and microbial metabolites. Changes in intestinal bacteria may influence inflammation, protein misfolding, or neural signaling — processes implicated in Parkinson’s — making the gut a plausible site for early biological warnings.
Are there risks in telling people they might develop Parkinson’s based on gut bacteria?
Yes. The study noted that some healthy individuals had microbiomes resembling those of at-risk people, but it’s unknown whether they will develop the disease. Premature risk labeling could cause anxiety without clear preventive actions, so researchers stress the necessitate for caution and further study before any clinical leverage.
